Thermo Fisher Scientific's recently-acquired Brammer Bio is completing $100 million in capital expansion projects, as the viral vector CDMO looks to satisfy growing demand for gene therapies for clinical and commercial use . . .

Get GEN Edge Today!

See More on the Edge

Continue reading this article and more
with a GEN Edge subscription

Start Your 30-Day Free Trial Now

Log In Join GEN Edge